🟠 Moderate Evidence
- A Fungal Infection at the Nexus of Travel, Climate, and Delayed Recognition
- Diagnostic Delays and Misclassification Remain Central Challenges
- Treatment Requires Integration of Medical and Surgical Approaches
- Global Burden, Travel Medicine Implications, and the Case for Heightened Awareness
- Frequently asked questions
Chromoblastomycosis, a chronic subcutaneous fungal infection caused by dematiaceous fungi, is gaining renewed attention in clinical medicine as increasing case reports highlight diagnostic and therapeutic challenges that have historically delayed treatment. According to a clinical case presentation published in The New England Journal of Medicine, Volume 394, Issue 23 (June 2026), the disease remains underdiagnosed in non-endemic regions despite its potential for significant morbidity if left untreated.
Key takeaways
- Chromoblastomycosis is a chronic fungal skin infection endemic to tropical and subtropical regions, with cases now appearing in temperate climates
- Delayed diagnosis is common due to misclassification as other skin conditions, prolonging disease progression and disability
- Clinical recognition and early biopsy with histopathological examination are essential for timely diagnosis and treatment initiation
- Antifungal therapy combined with surgical intervention offers the best chance for disease control and cure
Case at a Glance
| Source | The New England Journal of Medicine |
| Article type | Clinical case presentation and review |
| Focus | Diagnostic and therapeutic challenges in chromoblastomycosis |
| Publication date | June 18, 2026 (Volume 394, Issue 23) |
| Clinical relevance | Underdiagnosed condition with significant morbidity if untreated |
Geographic Distribution and Risk Factors in Chromoblastomycosis
Endemic regions and populations most affected by dematiaceous fungal infections
Source: NEJM clinical case presentation, June 2026 | Georgian Medical Journal News
A Fungal Infection at the Nexus of Travel, Climate, and Delayed Recognition
Chromoblastomycosis is caused by a group of dematiaceous (melanin-containing) fungi, most commonly Fonsecaea pedrosoi, Phialophora verrucosa, and Cladophialophora carrionii, according to the clinical review in The New England Journal of Medicine. The infection typically enters the body through minor traumatic inoculation—commonly via thorn pricks, soil exposure, or cuts—making it an occupational hazard for agricultural workers, gardeners, and construction workers in endemic tropical regions.
The disease establishes itself as a chronic localized skin infection, most often affecting the lower extremities. What distinguishes chromoblastomycosis from common dermatological conditions is its progressive nature: without treatment, lesions gradually spread, become scarred and fibrotic, and can lead to severe functional impairment and increased infection risk. The insidious progression often means patients do not seek care until significant tissue damage has occurred.
Diagnostic Delays and Misclassification Remain Central Challenges
The NEJM case presentation highlights a critical clinical gap: chromoblastomycosis is frequently misdiagnosed as psoriasis, eczema, warts, or other more common skin conditions, particularly in clinicians outside endemic zones. Early lesions may present as small, asymptomatic papules or plaques, creating diagnostic confusion. This delay in recognition can extend for years before definitive diagnosis is established.
The diagnostic gold standard is histopathological examination of a skin biopsy, which reveals the characteristic “sclerotic bodies” (also called muriform cells)—dark, thick-walled fungal spores with distinctive internal septation visible under light microscopy. Without a high index of clinical suspicion, this diagnostic step may never be pursued. Culture confirmation, though definitive, is slow and often requires specialized mycology expertise not uniformly available in all healthcare settings. See related coverage on quality and diagnostic standards in clinical microbiology.
Treatment Requires Integration of Medical and Surgical Approaches
According to the NEJM clinical review, chromoblastomycosis is notoriously difficult to cure with antifungal monotherapy alone. First-line antifungal agents include itraconazole, terbinafine, and voriconazole, with lengthy treatment courses (often 6–12 months or longer) required to achieve clinical cure. Itraconazole remains the most extensively studied agent, though response rates vary significantly depending on disease duration, lesion size, and fungal species involved.
The most effective approach combines antifungal therapy with surgical excision or thermotherapy of lesions. Cryotherapy, laser ablation, and surgical removal all play important roles, particularly for localized disease. In extensive or refractory cases, combination antifungal therapy may be considered, though evidence remains limited. For patients with chronic infections affecting daily function, early aggressive treatment offers the best outcome.
Global Burden, Travel Medicine Implications, and the Case for Heightened Awareness
The publication of this clinical case in The New England Journal of Medicine underscores a growing reality: as international travel and labor migration increase, clinicians in non-endemic regions are encountering chromoblastomycosis with greater frequency. A traveller returning from Brazil, a worker who spent years in agricultural work in Mexico, or an immigrant from Madagascar may present to a dermatologist or primary care physician in Europe or North America with an unrecognized fungal infection.
This calls for a two-pronged public health response: education of healthcare providers in travel medicine and dermatology about the clinical presentation of chromoblastomycosis, and strengthened access to diagnostic mycology services in resource-limited endemic regions where disease burden is highest. The World Health Organization’s focus on neglected tropical diseases includes recognition that fungal infections, though historically underemphasized, pose significant disability and mortality in affected populations.
Chromoblastomycosis, a chronic dematiaceous fungal infection most commonly caused by Fonsecaea pedrosoi, requires high clinical suspicion, histopathological confirmation via skin biopsy, and combined antifungal and surgical treatment for optimal outcomes.
— Clinical review, The New England Journal of Medicine, Volume 394, Issue 23 (June 2026)
What this means
Related Coverage
Medically reviewed by Prof. Giorgi Pkhakadze, MD, MPH, PhD. Spotted an error? Contact the editorial team.
